Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | NQO2 | P16083 | 6/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678780 | 1.00 | KDM4E (0.53) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL535539 | 0.85 | KDM4E (0.51) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL31039239 | 0.85 | KDM4E (0.51) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL26040460 | 0.85 | KDM4E (0.54) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL536169 | 0.83 | KDM4E (0.50) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL26040458 | 0.83 | NQO2 (0.46) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL17979068 | 0.83 | KDM4E (0.50) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL30657473 | 0.83 | KDM4E (0.50) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL26639879 | 0.83 | KDM4E (0.50) | KDM4ENQO2ABL1POLBGAA | |
| SCHEMBL21349700 | 0.83 | KDM4E (0.53) | KDM4ENQO2ABL1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087634-A1 | TREM2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025235957-A1 | P53 MUTANT STABILIZER AND USES THEREOF | FRONTIER MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| EP-4524135-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2025-03-19 | — | — | EP | disclosed |
| CN-119212988-A | Kinesin KIF18A inhibitor and application thereof | 上海湃隆生物科技有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4450501-A1 | CDK9 INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-117624168-A | Condensed ring heterocyclic compound and preparation method and application thereof | 德明药泰生物技术（深圳）有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2023217230-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| EP-2144898-B1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| CN-101679377-A | Heterocyclic hydrazide compound and pesticidal use of the same | SUMITOMO CHEMICAL CO | 2010-03-24 | — | — | CN | disclosed |
| EP-2144898-A2 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008130021-A2 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130021-A2 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | KDM4E 212/4885NQO2 40/4885ABL1 227/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | KDM4E 4039/4885NQO2 48/4885ABL1 37/4885 |
| US-20250163043-A1 | CDK9 INHIBITOR AND USE THEREOF | CDK9, CDK19, CDKL1 | KDM4E 510/4885NQO2 299/4885ABL1 139/4885 |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, CAT, DNPH1 | KDM4E 2297/4885NQO2 65/4885ABL1 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.